UA111088C2 - Pyridinylpyrazoloquinoline compound - Google Patents

Pyridinylpyrazoloquinoline compound

Info

Publication number
UA111088C2
UA111088C2 UAA201403315A UAA201403315A UA111088C2 UA 111088 C2 UA111088 C2 UA 111088C2 UA A201403315 A UAA201403315 A UA A201403315A UA A201403315 A UAA201403315 A UA A201403315A UA 111088 C2 UA111088 C2 UA 111088C2
Authority
UA
Ukraine
Prior art keywords
hydrogen atom
compound
increase
cgmp
pyridinylpyrazoloquinoline
Prior art date
Application number
UAA201403315A
Other languages
Ukrainian (uk)
Inventor
Йошіхіко Норіміне
Кунітоші Такеда
Коджі Хагівара
Юічі Сузукі
Юкі Ішіхара
Нобуакі Сато
Original Assignee
Ейсей Р Енд Д Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ейсей Р Енд Д Менеджмент Ко., Лтд. filed Critical Ейсей Р Енд Д Менеджмент Ко., Лтд.
Priority claimed from PCT/JP2012/075748 external-priority patent/WO2013051639A1/en
Publication of UA111088C2 publication Critical patent/UA111088C2/en

Links

Abstract

Винахід стосується сполуки або її фармакологічно прийнятної солі, представленої формулою (I), (I)де Rє атомом водню; Rє ароматичною кільцевою групою і т. д.; Rє атомом водню і т. д.; Rє атомом водню; Rє оксепанільною групою і т. д., Rє атомом водню,що має РDЕ9-інгібіторну дію, завдяки якій очікується підвищення концентрації внутрішньомозкового cGMP, де РDЕ9-інгібіторна дія та підвищення сGМР приводять до поліпшення протікання навчання та розвитку пам'яті, та де сполука (І) характеризується можливим застосуванням як терапевтичного засобу від когнітивних дисфункцій при хворобі Альцгеймера.The invention relates to a compound or pharmacologically acceptable salt thereof represented by formula (I), (I) wherein R is a hydrogen atom; R is an aromatic ring group, etc .; Is a hydrogen atom, etc .; R is a hydrogen atom; With an oxepanil group, etc., with a hydrogen atom having a PDE9 inhibitory activity, due to which an increase in the concentration of intracerebral cGMP is expected, where a PDE9 inhibitory action and an increase in cGMP lead to improved learning and memory development, (I) is characterized by the possible use as a therapeutic agent for cognitive dysfunction in Alzheimer's disease.

UAA201403315A 2011-10-07 2012-04-10 Pyridinylpyrazoloquinoline compound UA111088C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544860P 2011-10-07 2011-10-07
PCT/JP2012/075748 WO2013051639A1 (en) 2011-10-07 2012-10-04 Pyrazoloquinoline derivative

Publications (1)

Publication Number Publication Date
UA111088C2 true UA111088C2 (en) 2016-03-25

Family

ID=55798672

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201403315A UA111088C2 (en) 2011-10-07 2012-04-10 Pyridinylpyrazoloquinoline compound

Country Status (1)

Country Link
UA (1) UA111088C2 (en)

Similar Documents

Publication Publication Date Title
CY1117427T1 (en) PYRAZOLOKINOLINE PRODUCTION AS INPUTS PDE9
NI201200089A (en) N1 INHIBITORS - ACETYL PYRAZOLOSPIROKETONE - CoA CARBOXYLASE
EA201491936A1 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
ECSP13013038A (en) ACETIL-COA CARBOXILASA REPLACED INHIBITORS
UY33694A (en) ? N1 / N2-LACTAMA ACETIL-COA CARBOXYLASE INHIBITORS ?.
PE20121617A1 (en) OXAZINE DERIVATIVES AS BACE INHIBITORS
EA201490445A1 (en) CYCLOPROPANAMINE COMPOUND
UY31606A1 (en) DERIVATIVES OF AZABYCYCLIC CARBOXAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
CR20130588A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
CO6311079A2 (en) AMINODIHYDROTIAZINE DERIVATIVES AS INHIBITORS OF THE BACE ENZYME FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GT201200219A (en) PIRAZINE DERIVATIVES AND USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
UY32543A (en) ANALOGS OF ISOXAZOL-3 (2H) -ONA AS THERAPEUTIC AGENTS
GT201300179A (en) NEW HETEROCICLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
MA33939B1 (en) 5-alkynyl-PYRIMIDINE
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
ECSP14013221A (en) Phenyl-3-aza-bicyclo [3.1.0] hex-3-yl-methanones and its use as a medicine.
BR112015029348A2 (en) bace inhibitors
ECSP13012664A (en) CRYSTAL FORMS OF SALT CHLORHYDRATE OF (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONIL-2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDEN [2,1- B] PIRIDIN-6-CARBONITRILE AND ITS USE AS HSD INHIBITORS 1
PE20151718A1 (en) PYRIDINYLPIRAZOLOQUINOLINE COMPOUNDS
EA201790626A1 (en) MACRO CYCLIC INHIBITORS LRRK2-KINASE
PE20142450A1 (en) DIFLUORO-HEXAHYDRO-CYCLOPENTAOXACINYLS AND DIFLUORO-HEXAHYDRO-BENZOOXACINYLS AS BACE1 INHIBITORS
MX2013008699A (en) Compounds for the reduction of î²-amyloid production.